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Abstract
Context: Taste and smell abnormalities (TSA) occur throughout the cancer trajectory regardless of cancer primary site and
contribute to cancer-associated malnutrition. TSA etiology is poorly understood. Tumor-related inflammation is a possible cause.
Objective: This study examined the prevalence, characteristics, and severity of TSA in advanced cancer and explored the
relationship between TSA and nutritional status. No previous study combined subjective and objective measures for both
taste and smell assessment in this population. Method: Consecutive advanced cancer hospice patients were recruited. A
modified version of the “Taste and Smell Survey” assessed subjective TSA. Validated taste strips and “Sniffin’ Sticks” were the
objective measures. The abridged patient-generated subjective global assessment evaluated nutritional status. Results: A 93%
prevalence of TSA in 30 patients with advanced cancer was identified. When subjective and objective evaluations were combined,
28 had taste abnormalities, 24 smell abnormalities, and 24 both. Taste changes included “persistent bad taste” (n ¼ 18) and
changes in how basic tastes were perceived. Half reported smell was not “as strong” as prediagnosis, while more than half (n¼ 16)
had an objective smell abnormality. Most (97%) were at risk of malnutrition. Fatigue, dry mouth, early satiety, and anorexia were
common nutrition-impact symptoms. No statistically significant relationship was found between TSA and malnutrition scores.
Conclusions: TSA were highly prevalent. Subjective taste and smell changes did not always accord with objective TSA, suggesting
both assessments are valuable. TSA characteristics varied, and particular foods tasted and smelled different and were not enjoyed
as before. TSA are common, high-impact problems in advanced cancer.
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Introduction
Malnutrition is a complex condition, prevalent in up to 90% of
persons with advanced cancer.1 Nutritional symptoms are com-
mon and contribute to malnutrition risk. Taste and smell
abnormalities (TSA) can impact food enjoyment and intake,
nutritional status, and quality of life (QoL).1,2 The prevalence
of TSA ranges from 60% to 86% in advanced cancer.3 Distur-
bances in taste and smell may occur alone, but more frequently
co-occur with other nutrition impact symptoms (NIS) like dry
mouth, early satiety, fatigue, nausea or pain.4,5 When such
symptoms co-occur, the cause and relative impact of individual
symptoms can be difficult to determine.
Although TSA seem common, the absence of a gold stan-
dard assessment means evaluation is uncommon in routine
clinical practice. Inconsistent taste and smell terminology con-
tribute to this. The words “flavor” and “taste,” for example, are
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interchangeable in everyday speech. Taste is just one aspect of
flavor (which also incorporates consistency, smell, and tem-
perature).6 Some small studies suggest a relationship between
smell and taste.7 However, a large study concluded that
smell had little influence on taste.8 Subjective and objective
measures capture TSA prevalence, characteristics and
severity.1,9-11 Subjective measures provide information on
individual chemosensory experiences. Objective measures
determine the ability to recognize tastes and smells.
Possible mechanisms are poorly understood and understu-
died,6,12,13 but inflammation is identified as a possible cause.14
Research has largely focused on head and neck cancer TSA as a
consequence of chemotherapy and/or radiotherapy. TSA are
reported in treatment-naı̈ve and patients with advanced cancer,
regardless of cancer primary site.3,12,13,15-17 This suggests that
the tumor itself may play a role in TSA etiology.
Increased understanding of the extent and impact of TSA in
advanced disease will progress the development of suitable
screening/assessment strategies and clinical interventions. This
study aimed to examine the prevalence, characteristics, and
severity of TSA in advanced cancer by both subjective and
objective assessments. We hoped to evaluate the clinical utility
of available assessment methods. We also explored the rela-
tionship between TSA and nutritional status.
Methods
A prospective cross-sectional observational study was con-
ducted in an in-patient palliative care unit. Consecutive
admissions with an advanced cancer who had a life expec-
tancy >7 days and an Eastern Cooperative Oncology Group
(ECOG)18 performance status 3, were identified at multi-
disciplinary team meetings and invited to participate. Those
with a diagnosis of dementia, current oral candidiasis, Nau-
sea, vomiting or considered too unwell were excluded.
Recruitment occurred over 7 consecutive weeks. The study
was approved by the Medical Ethics Committee, St Vincent’s
University Hospital, Dublin. Participants provided written
informed consent after verbal and written explanation. Parti-
cipant characteristics were obtained from medical health-care
records. Observational measures were conducted at the bed-
side by a student dietitian (NMcG) in 30 to 40 minute inter-
actions. Participants were advised not to drink, eat, or smoke
for 1 hour beforehand.
Taste and Smell Survey
A modified version of the “Taste and Smell Survey” (TSS;
Figure 1)19 was used to explore the prevalence, characteristics
and severity of taste changes (TC) and smell changes (SC)
since becoming ill. Four medication questions in the original
version were omitted; 12 items remained (7 for taste; 5 for
smell). Although not validated, it has been used before in the
oncology setting,11,20-22 including advanced cancer.1
The TSS responses generated a chemosensory complaint
score. One point was awarded for each reported complaint. A
further point was awarded when it was “mild/moderate” or
“rarely/sometimes” and a further 2 if “severe/incapacitating”
or “often/always.” Taste changes yielded a potential score of 0
to 10 (0 ¼ no changes; 10 ¼ multiple severe changes). Smell
changes ranged from 0 to 5 (0 ¼ no changes; 5 ¼ multiple,
severe changes). A combined chemosensory complaint score of
0 to 15 was also calculated. Two unscored, open questions
(Q10, 12) allowed participants describe how TSA impacted
QoL. Question 6 was also unscored.
Objective Assessment
Objective measures determined the prevalence and character-
istics of impaired taste (ITP) and smell perception (ISP). Nei-
ther measured severity.
The ability to recognize and identify 4 basic taste modal-
ities (bitter, salty, sour, and sweet) was assessed by validated
taste strips (Burghart Messtechnik GmbH, Wedel, Ger-
many).23 Umami is not widely known in Ireland and was not
assessed. The taste strips were applied to the tongue for
whole-mouth testing. Strips were presented randomly, except
bitter which was always done last (due to lasting taste). Strips
were placed onto the centre of the tongue and the mouth then
closed. After a timed 10 seconds (timed by iPhone 5, Apple,
San Francisco, California), the strip was removed and the
participant asked to identify the taste. After each strip the
participant swallowed 10 to 20 ml of still cold water (Tesco,
Perthshire, United Kingdom) to cleanse the palate. The
researcher waited 30 seconds before the next taste strip. Each
correct answer got a score of one (with a possible maximum
score of 4). Each incorrect answer indicated a taste abnorm-
ality (TA). When a taste was not identified, participants were
asked to guess.
The “Sniffin’ Sticks” (Burghart Messtechnik GmbH,
Wedel, Germany) odor identification test assessed smell.24,25
Twelve odor-filled pens (numbered 1-12) were used in numer-
ical sequence. Each was uncovered and held 2 cm from the tip
of the nose for four timed seconds (iPhone 5, Apple, San Fran-
cisco, California). When each pen was offered, a card with 4
odor pictures/descriptors (eg, glue, grass, leather, smoke) was
also presented. The participant chose the descriptor that iden-
tified the odor. Similar to taste, participants were encouraged to
guess if unsure. A timed one-minute pause was observed
between each pen. A score of one was given for each correct
answer (maximum possible score was 12). Scores were then
categorized (as per instruction manual): Normal smell: 10 to
12; Smell Abnormality (SA): hyposmia (reduced): 6 to 9; anos-
mic (absence): 5.
Nutritional Screening
An abridged version of the original Patient-Generated Subjec-
tive Global Assessment26 (abPG-SGA) was used to assess
nutritional status (Figure 2). This is a validated screening tool
in oncology.27 It evaluated 4 areas: (1) self-reported height,
weight, and weight history; (2) recent dietary intake; (3) NIS
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The purpose of this survey is to see how people experience taste and smell changes. Please answer the following questions as best you can.
1. Have you noticed any changes in your sense of taste?
If yes, please describe: ______________________________________________________
Yes c No c
2. Have you noticed any changes in your sense of smell?
If yes, please describe: ______________________________________________________
Yes c No c
3. Have you ever noticed that a food tastes different than it used to?
If yes, please describe: ______________________________________________________
Yes c No c
4. Have you ever noticed that a food smells different than it used to?
If yes, please describe: ______________________________________________________
Yes c No c







6. The persistent taste is
1. salty
2. sweet (like sugar)
3. sour (like lemon or vinegar)
4. bitter (like black coffee or tonic water)
5. other (specify) _________________________________________
(circle ALL that apply)





4. I cannot taste it at all
(circle BEST answer)




4. I cannot taste it at all
(circle BEST answer)




4. I cannot taste it at all
(circle BEST answer)




4. I cannot taste it at all
(circle BEST answer)




4. I cannot smell at all






10. How has your abnormal sense of taste affected your quality of life? _________________






12. How has your abnormal sense of smell affected your quality of life? ________________
Figure 1. Modified taste and smell survey (from Heald et al 1998).
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including taste and smell; (4) current activity and function.
Scores ranged from 0 to 36; 6 has high sensitivity and spe-
cificity for malnutrition risk.27
Data Analysis
Data analysis was performed using SPSS® version 24 (IBM
Corporation, New York). Descriptive statistics were
reported as means (+SD), medians (range) and percentages.
All results were rounded to the nearest whole number. Bin-
ary logistic regression investigated the relationship between
age and TSA. Cross-tabulation and a w2 statistical test
examined the relationship between categorical variables.
Linear regression evaluated the relationship between TSA




Fifty-two consecutive advanced cancer admissions were iden-
tified. Of those, 30 participated and completed the study. Rea-
sons for nonparticipation were; changed clinical status (n ¼
10), declined (n ¼ 8), died (n ¼ 2), and discharged (n ¼ 2).
Mean age was 68 years (SD ¼+12). Cancer types were solid
tumors (29/30) and multiple myeloma (1/30). Baseline study
population characteristics are in Table 1.
Taste and Smell Abnormality Prevalence
The prevalence varied by assessment type (Figure 3). Subjec-
tive prevalence was higher by TSS (taste: n ¼ 28; smell n ¼
21) than by abPG-SGA (a single question each for taste and
smell; taste: n ¼ 17; smell: n ¼ 10). Of those with subjective
TC (n ¼ 28), 12 had no objective ITP. Everyone with objec-
tive ITP (n ¼ 16) also reported subjective TC on TSS. Eight
with subjective SC had no objective ISP. Three hyposmic
participants reported no subjective SC.
Multiple TSA were reported by some, others a single
abnormality. TC were more common than SC. Seven with
subjective TC reported no subjective SC. Everyone with sub-
jective SC (n ¼ 21) also had subjective TC. In objective tests,
prevalence was similar for TA and SA: 10 had both and the rest
either TA (n ¼ 6) or SA (n ¼ 6) alone. Binary logistic regres-
sion showed no statistically significant relationship between
gender (P¼ .338), treatment type (P ¼ .626) or smoking status
(P ¼ .073) and TSA.
Taste and Smell Abnormality Characteristics
The characteristics of TSA are in Figure 4. The single most
common subjective complaint was a persistent bad taste (n ¼
18). This was described variously including “bitter,”
“coppery,” “dirty,” “metallic,” “poison,” “salty,” “sickening,”
and “like something gone off.” In half, the bad taste occurred
“often” (n ¼ 5) or “always” (n ¼ 4).
Taste changes were reported for all taste modalities. Over
half (n ¼ 16) said specific foods tasted different since becom-
ing ill and were not as enjoyable. Some reported food “tastes
bland” (n ¼ 6) or “has no taste at all” (n ¼ 5). Words like
PLEASE COMPLETE BOXES 1-4 
BOX 1: WEIGHT 
In summary of my current and recent weight: 
I am about ______feet _______inches tall 
I currently weigh about:  _____stone _____pounds
One month ago I weighed about _____stone ____pounds   
Six months ago I weighed about _____stone ____pounds  
During the past two weeks my weight has:  
Decreased   Not changed  Increased   
BOX 2: FOOD INTAKE 
As compared to my normal intake, I would rate my food intake during the 
past month as: (please tick) 
Unchanged 
More than usual 
Less than usual 
If “Less than usual”:
I am now taking: 
Normal food but less than normal amounts 
Little solid food 
Only liquids  
Only nutritional supplements 
Very little of anything 




BOX 4: ACTIVITIES AND FUNCTION 
Over the past month, I would generally rate my activity as: (please circle) 
Normal with no limitations 
Not my normal self, but able to be up and about with fairly normal activities 
Not feeling up to most things, but in bed or chair less than half the day 
Able to do little activity and spend most of the day in bed or chair 
Pretty much bedridden, rarely out of bed 
BOX 3: SYMPTOMS 
I have had the following problems that have kept me from eating enough during 
the past two weeks (tick all that apply): 
No problems eating 
No appetite, just did not feel like eating 
Nausea  





Things taste funny or have no taste 
Smells bother me 
Problems swallowing 
Feel full quickly 
Fatigue 
Pain:   where__________ 
Other*_________________  
*e.g. depression, money or dental problems 
Figure 2. Abridged patient-generated subjective global assessment
(abPG-SGA; Ottery 1996; Gabrielson et al. 2013).
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“horrible,” “undesirable,” and “disgusting” were used to
describe the loss of appeal of food. Eating was “not the same”
as before (n ¼ 2) and TSA had turned some off eating (n ¼ 4).
Subjective TSS assessment captured both increased and
decreased taste perception whereas objective measures could
only detect ITP. Salty (n ¼ 15, 50%) and sweet (n ¼ 14, 47%)
tastes had most often changed. “Salty” was predominantly
weaker/could not taste and “sweet” mostly stronger. Across the
4 tastes, there were 22 individual complaints of stronger tastes
and 18 weaker/could not taste.
In objective tests over half (n ¼ 16/30) could not correctly
identify all 4 taste modalities. Two did not detect any of the 4; 1
detected 1, 8 detected 2, and 5 detected 3. Sour was the least
identified and sweet the most easily identified of the taste
modalities.
Seven reported certain foods (eg, coffee, fried foods, pasta,
and stuffing) smelled different since becoming ill. Objective
tests found 16 had ISP. In contrast, only 10 reported subjective
smells as weaker/could not smell and a further 5 said smells
were stronger. Objective tests did not allow increased acuity to
be tested.
Taste and Smell Abnormality Severity
Subjective chemosensory complaint scores are presented in
Figure 5. The median taste complaint score ¼ 4.5 (range 0-9)
and the median smell score ¼ 2 (range 0-4). The combined
chemosensory complaint score ¼ 7 (range 0-11). The severity
of subjective TC (n¼ 28) were insignificant (n¼ 3), mild (n¼
8), moderate (n¼ 9), severe (n¼ 5), and incapacitating (n¼ 3).
Subjective SC (n ¼ 22) were insignificant (6), mild (n ¼ 8),
moderate (n ¼ 7), and incapacitating (n ¼ 1).
Taste and Smell Abnormalities and Quality of Life
Of those with a TSA, almost half (n¼ 13/28) reported that QoL
was affected. Eleven of these had subjective TC (n ¼ 11/13),
while 5 had objective ITP (n ¼ 5/13). Only 4 with SC and 3
with ISP reported reduced QoL.
Nutritional Status and NIS
Ninety-six per cent with TSA (n ¼ 27/28) had an abPG-SGA
score 6, which indicated malnutrition risk. The median abPG
SGA score (for those with a full data set and at least one TSA;
Table 1. Study Demographic Characteristics.



























Underweight (<18.5 kg/m2) 7
Normal (18.5-24.9 kg/m2) 11
Overweight (25-29.9 kg/m2) 6


































Taste & Smell Survey (subjecve)
abPG-SGA (subjecve)
Objecve Measure
Figure 3. Prevalence of subjective versus objective measures of taste
and smell abnormalities.
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n ¼ 25) was 13/36 (range: 4-27). Body mass index (BMI)28
could not be calculated for 3 participants due to missing data.
The 2 without TSA were also at malnutrition risk.
Twenty (20/27; 74%) had normal or above normal BMI.
All 7 underweight patients had TSA. In those with TSA and
malnutrition risk (n ¼ 27) 12 lost weight, 10 gained weight,
and 3 were weight stable in the prior 6 months. Most with
TSA reported eating “less than usual” during the previous 2
weeks (n ¼ 17/28). The majority (n ¼ 12/17) ate “normal
foods but less than normal amounts.” The rest reported eat-
ing “little solid food.” NIS were reported by 96% (n ¼ 27/
28) with TSA (Figure 6). The median number of NIS
reported was 6.5/14, (range: 0-13). The regression model
showed a nonsignificant relationship (P ¼ .585) between
TSA and malnutrition scores.
Discussion
Combined subjective and objective assessment yielded high
TSA prevalence, but this varied with assessment method. Many
reported subjective TC and SC, but without objective abnorm-
ality. Persistent bad taste was the most common abnormality.
Changes in how food tasted and smelled, and increases and/or
decreases in taste and/or smell perception were frequent.
No previous studies have combined subjective and objective
tools to assess taste and smell in advanced cancer. The char-
acteristics of TSA varied depending on assessment method and
these variations challenge our understanding of the etiology
and pathophysiology of TSA.
This advanced cancer study population had mostly solid
tumors, poor performance status, and a representative age
profile. TSA sometimes occurred together, but in other
instances TC and/or ITP were present when smell was normal
and vice versa. Participants seemed less aware of SC, and so it
was not surprising that TC were more common and perceived
as more severe than SC. The discrepancy in TSA prevalence
between TSS and abPG-SGA may relate to the variation in time
frame; the abPG-SGA captures symptoms in the 2 weeks prior
to assessment, but the TSS captures any change in taste or smell
since diagnosis.
Malnutrition risk was high despite mostly normal BMI.
NIS were common and frequently co-occurred. A common
theme, in our study and the work of others,29,30 was that food
lacked taste or was bland. This interfered with food enjoy-
ment, most notably main meals and eating out.
Our TSA prevalence at 93% was higher than other studies in
advanced cancer (50%-90%).3,14 This may reflect the fact that
unlike other studies, both taste and smell were assessed with
both objective and subjective measures.
Objective ITP and ISP were recorded in equal measure, but
did not co-occur in all TSA participants. Subjective TC were
more common than SC. This supports the findings of others
who used TSS.1,2 Another study31 also observed lower SC
awareness using a different assessment. This may explain why
in our study subjective TC were considered more severe and
had a higher QoL impact than SC, ITP, or ISP. Contrary to
other work1,2 in advanced cancer, the impact of TSA on QoL
was relatively low overall.
Altered taste and smell were found by both subjective and
objective measures. Subjective TC were most common for
“salt” (mostly weaker) and “sweet” (mostly stronger). This
supports similar subjective findings in treatment-naı̈ve patients
↓ = reduced acuity
↑ = increase acuity
Taste OR Smell 
Abnormality 
n = 28 
Smell 










Objecve   




























n =  18
Objecve 









Figure 4. Characteristics of subjective and objective taste and smell abnormalities (N ¼ 30).
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with cancer.11 Stronger “sweet” taste intensity has been
reported during chemotherapy9,10 while other advanced cancer
studies noted both increased and decreased “salt” sensitivity1
and decreased “sweet” sensitivity.3,29
Despite fewer reported subjective TC for “bitter” and
“sour,” objective ITP was most frequent for these modalities.
Others29 also documented poor “bitter” detection in a similar
cohort, with different objective measures. Some investiga-
tors1 found increased “bitter” and “sour” sensitivity on the
TSS; we did not. In a similar cohort, “stronger” taste acuity
was more common than “weaker” for all taste modalities.2
Eighty three per cent of participants had SC and/or ISP. This
exceeded previously reported prevalence of 60%.31
Smells were most commonly weaker. Evidence from others
suggests TSA can impact weight loss and nutritional sta-
tus,1,2,10,15 but we did not identify any association.
This study had several limitations. A small sample size and
high TSA prevalence limited statistical power. A larger sam-
ple size would help determine associations between TSA, NIS
and malnutrition risk across different cancer types. The study
population was predominantly female. This may have
impacted results as women are thought more sensitive to taste
and smell than men.23,32 The assessment tools employed were
used in previous TSA cancer studies,1,9,12,20,21 facilitating
comparison of results. Despite a literature search, no validated
subjective TSA assessment tool was identified.13 The TSS
was interviewer-assisted by a single researcher to maximize
item response rate.
Confusion about terminology and recognition of specific
tastes was a methodological challenge. In particular, the taste
descriptors “sour” and “bitter” were problematic. Some parti-
cipants detected and recognized the taste, but failed to correctly
label it. Others did not understand it. This may have interfered
with the integrity of the TSS and the taste strips results. The
struggle to articulate taste and smell experiences may be com-
pounded by the fact that clinicians seldom enquire about
TSA.33 Similar concerns were noted in the “Sniffin’ Sticks”
test as some of the smell options were unfamiliar. The “bitter”
taste strip was always presented last, and this may have made it
more susceptible to guess work. With objective tests only nor-
mal or reduced perception was detected. Increased perception
was not captured. This may explain why subjective prevalence
was higher than objective.
The high prevalence of TSA, malnutrition risk and NIS is
clinically relevant in advanced cancer given that symptom
management is central to palliative care. The use of TSA and
malnutrition screening tools with common terminology could,
over time, educate patients about the importance of TSA and
common NIS and their impact on food enjoyment. Persistent
bad taste is a significant common problem. Consideration
should be given to devising simple, effective strategies to man-
age this symptom in advanced cancer. In order to fully under-
stand the natural history of TSA, future studies should combine
subjective and objective assessment in a longitudinal study
from diagnosis to survivorship or end of life. We did not
examine food intake. Quantitative dietary assessment should
be considered in future studies to gain greater insight into the
impact of TSA on food consumption, dietary patterns and
malnutrition risk. Future studies should include matched
healthy volunteers as a control group and time since treatment
completion should be documented to better understand treat-
ment effects. We used a modified version of the TSS; the
current scoring system does not adequately differentiate TSA
severity. We suggest a more comprehensive scoring system to
better determine severity should be considered. Taste and
smell survey validation is needed and may move us closer
to a TSA assessment gold standard and facilitate earlier detec-




































Combined Taste & Smell Change Scores 
(Score range: 0-15)
Figure 5. Subjective chemosensory complaint scores.
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Conclusion
The prevalence of TSA in this advanced cancer cohort was
high. Those with subjective TC and/or SC did not necessarily
have objective ITP and/or ISP. This suggests that both assess-
ments are needed for comprehensive evaluation. TSA abnorm-
ality characteristics varied, indicating a need for individualized
assessment and management. Persistent bad taste was the most
common complaint. Changes in taste perception were common
with “salty” predominantly weaker and “sweet” mostly stron-
ger. Over half were unable to correctly identify all 4 taste
modalities and a similar number reported that particular foods
tasted different and were not enjoyed as before. Smell percep-
tion was most commonly reported as weaker. Taste abnormal-
ities were more severe than smell and had a greater impact on
food enjoyment and QoL. Almost all participants were at mal-
nutrition risk. All except one had NIS and most had multiple
symptoms. No previous study combined the use of subjective
and objective measures for both taste and smell assessment in
advanced cancer. Our results contribute to the current, limited
evidence-base in this field. Taste and smell abnormalities are a
common problem in a heterogeneous advanced cancer popula-
tion in hospice care.
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